Last updated: February 13, 2026
What is the current market landscape for NDC 72305-0100?
NDC 72305-0100 refers to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor used primarily in oncology. As of 2023, it is approved for multiple cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, and others. Its competitive landscape includes Pembrolizumab (Keytruda) and other immunotherapies.
How does the market size of Nivolumab compare with peers?
The global immunotherapy market value for PD-1 inhibitors was estimated at approximately $20 billion in 2022, projected to grow at about 10% CAGR through 2027. Nivolumab held roughly 40% of this market segment, equaling an approximate revenue of $8 billion in 2022.
Key competitors:
| Drug |
Estimated Market Share (2022) |
Approved Indications |
Price per Dose (USD) |
| Nivolumab |
40% |
Melanoma, NSCLC, RCC, others |
$1500-$1700 |
| Pembrolizumab |
35% |
Melanoma, NSCLC, MSI-H cancers |
$1600-$1800 |
| Atezolizumab |
10% |
Bladder, lung |
$1200-$1500 |
| Cemiplimab |
5% |
Cutaneous squamous cell carcinoma |
$1400-$1600 |
What are the current price projections?
Wholesale Acquisition Cost (WAC) Trends
In the US, Nivolumab's WAC has been relatively stable over 2020-2023, averaging around $1500-$1700 per 40 mg dose. Price adjustments are limited due to high competitor saturation and payer negotiations.
Projected Price Trends
-
Short-term (2023-2025): WAC is expected to remain stable, with slight reductions (~2-3%) due to increased biosimilar competition in clinical trial phases.
-
Medium-term (2025-2030): Entry of biosimilars could reduce prices by 15-25%. Prices per dose might decline to approximately $1250-$1350.
Biosimilar Impact
The FDA approved Relatlimab (Libtayo) and other biosimilars in development threaten to lower originator prices. Several biosimilars are in late-phase development, with potential approval as early as 2024.
What are the key regulatory and policy factors influencing price?
- Patent protection expiration slated for 2028 in the US.
- Medicare and Medicaid reimbursement policies increasingly favor biosimilar adoption.
- Pricing negotiations conducted by pharmacy benefit managers (PBMs) aim to shift procurement toward biosimilars, pressuring originator prices.
How might market dynamics evolve?
- Growth driven by use in first-line settings for lung and kidney cancers.
- Increased adoption in combination therapy regimens.
- Patent cliffs and biosimilar approvals may lead to significant price erosion post-2028.
What is the revenue projection outlook?
| Year |
Estimated Revenue (USD billions) |
Market Share (%) |
| 2022 |
8.0 |
40% |
| 2023 |
8.2 |
40-42% |
| 2025 |
7.0 |
35-37% (post-biosimilar entry) |
| 2030 |
5-6 |
25-30% |
Growth Assumptions:
- Compound annual growth rate (CAGR): approximately 2-3% pre-biosimilar emergence.
- Post-biosimilar: decline of 10-15% annually beginning in 2028.
Summary of market and pricing outlook
Nivolumab remains a significant revenue generator, with stable prices in the near term. Biosimilar competition and patent expiration in the next few years are projected to reduce prices substantially, impacting future revenue. Payer policies and clinical adoption trends are critical influencing factors.
Key Takeaways
- Current global market value estimated at $8 billion, with stable pricing at $1500-$1700 per dose.
- Biosimilar competition poised to erode prices by 15-25% by 2025.
- Patent expiry around 2028 will likely accelerate price declines.
- Market share could decline from 40% in 2022 to below 30% by 2030 amid increased biosimilar adoption and competitive therapies.
FAQs
1. What are the main competitors to Nivolumab?
Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), and Cemiplimab (Libtayo).
2. How soon will biosimilars impact Nivolumab prices?
Biosimilar approval and market entry are expected around 2024-2025, with significant additional price pressures by 2028.
3. What is the primary factor influencing future revenue projections?
The timing and extent of biosimilar market penetration and patent expiration.
4. Are there regional differences in pricing?
Yes. US prices are generally higher due to different reimbursement policies compared to Europe and emerging markets.
5. How might clinical trial outcomes affect pricing?
Positive approval and expanded indications can sustain higher prices; failures or delayed approvals can lead to discounting and revenue loss.
Sources:
[1] MarketWatch, "Immunotherapy Market Size, Share & Trends," 2023.
[2] FDA approvals database, 2023.
[3] IQVIA, "Global Oncology Market Data," 2023.
